Immune landscape of breast tumors with low and intermediate estrogen receptor expression

Immune checkpoint blockade (ICB) is currently approved for patients with triple-negative breast cancer (TNBC), whereas responses to ICB are also observed in a small subgroup of Estrogen Receptor (ER)-positive breast cancer. The cut-off for ER-positivity (≥1%) is based on likelihood of endocrine trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Voorwerk, Leonie, Sanders, Joyce, Keusters, Milou S., Balduzzi, Sara, Cornelissen, Sten, Duijst, Maxime, Lips, Esther H., Sonke, Gabe S., Linn, Sabine C., Horlings, Hugo M., Kok, Marleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182974/
https://www.ncbi.nlm.nih.gov/pubmed/37179445
http://dx.doi.org/10.1038/s41523-023-00543-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182974/
https://www.ncbi.nlm.nih.gov/pubmed/37179445
http://dx.doi.org/10.1038/s41523-023-00543-0

Ejemplares similares